181 related articles for article (PubMed ID: 34633090)
1. Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapy.
Widjaja L; Derlin T; Ross TL; Bengel FM; Werner RA
Prostate; 2022 Jan; 82(1):86-96. PubMed ID: 34633090
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy.
Widjaja L; Werner RA; Ross TL; Bengel FM; Derlin T
Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4077-4088. PubMed ID: 34041564
[TBL] [Abstract][Full Text] [Related]
3. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
[TBL] [Abstract][Full Text] [Related]
4. Renal outcomes of radioligand therapy: experience of
Gallyamov M; Meyrick D; Barley J; Lenzo N
Clin Kidney J; 2020 Dec; 13(6):1049-1055. PubMed ID: 33391748
[TBL] [Abstract][Full Text] [Related]
5. Third-line treatment and
von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
[TBL] [Abstract][Full Text] [Related]
6. Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with
Huang K; Schatka I; Rogasch JMM; Lindquist RL; De Santis M; Erber B; Radojewski P; Brenner W; Amthauer H
Ann Nucl Med; 2021 Mar; 35(3):314-320. PubMed ID: 33351172
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of
Gabela L; Mkhize T; Hadebe B; Harry L; Nxasana T; Ndlovu N; Pillay V; Masikane S; Patel M; Nyakale NE; Vorster M
Diagnostics (Basel); 2024 Mar; 14(6):. PubMed ID: 38534999
[TBL] [Abstract][Full Text] [Related]
8. Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [
Hartrampf PE; Weinzierl FX; Serfling SE; Pomper MG; Rowe SP; Higuchi T; Seitz AK; Kübler H; Buck AK; Werner RA
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158913
[TBL] [Abstract][Full Text] [Related]
9. PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under
Widjaja L; Werner RA; Ross TL; Bengel FM; Derlin T
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208246
[No Abstract] [Full Text] [Related]
10. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
11. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
12.
Zhang J; Kulkarni HR; Singh A; Schuchardt C; Niepsch K; Langbein T; Baum RP
J Nucl Med; 2019 Nov; 60(11):1579-1586. PubMed ID: 30850499
[TBL] [Abstract][Full Text] [Related]
13. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
14. Renal Safety of [
Rosar F; Kochems N; Bartholomä M; Maus S; Stemler T; Linxweiler J; Khreish F; Ezziddin S
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205686
[No Abstract] [Full Text] [Related]
15. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
Privé BM; Janssen MJR; van Oort IM; Muselaers CHJ; Jonker MA; de Groot M; Mehra N; Verzijlbergen JF; Scheenen TWJ; Zámecnik P; Barentsz JO; Gotthardt M; Noordzij W; Vogel WV; Bergman AM; van der Poel HG; Vis AN; Oprea-Lager DE; Gerritsen WR; Witjes JA; Nagarajah J
BMC Cancer; 2020 Sep; 20(1):884. PubMed ID: 32928177
[TBL] [Abstract][Full Text] [Related]
16. Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [
Hartrampf PE; Seitz AK; Weinzierl FX; Serfling SE; Schirbel A; Rowe SP; Kübler H; Buck AK; Werner RA
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4262-4270. PubMed ID: 35650263
[TBL] [Abstract][Full Text] [Related]
17. Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
Yaxley WJ; McBean R; Wong D; Grimes D; Vasey P; Frydenberg M; Yaxley JW
Investig Clin Urol; 2021 Nov; 62(6):650-657. PubMed ID: 34729965
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of tumor sink effect: Insights from
Tuncel M; Telli T; Tuncalı MÇ; Karabulut E
Ann Nucl Med; 2021 May; 35(5):529-539. PubMed ID: 33586096
[TBL] [Abstract][Full Text] [Related]
19. Kidney Doses in
Mix M; Renaud T; Kind F; Nemer U; Yousetzadeh-Nowsha E; Moalosi TCG; Ormrane AM; Meyer PT; Ruf J
J Nucl Med; 2022 Feb; 63(2):253-258. PubMed ID: 34088773
[TBL] [Abstract][Full Text] [Related]
20. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
